

# Lorenzo Brunetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8437813/publications.pdf>

Version: 2024-02-01

45  
papers

2,141  
citations

257101

24  
h-index

315357

38  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3751  
citing authors

#	ARTICLE	IF	CITATIONS
1	Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. <i>Cell Reports</i> , 2016, 17, 1453-1461.	2.9	223
2	Mutant NPM1 Maintains the Leukemic State through HOX Expression. <i>Cancer Cell</i> , 2018, 34, 499-512.e9.	7.7	209
3	DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. <i>Genome Biology</i> , 2017, 18, 176.	3.8	153
4	NPM1-mutated acute myeloid leukemia: from bench to bedside. <i>Blood</i> , 2020, 136, 1707-1721.	0.6	152
5	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. <i>Blood</i> , 2021, 137, 624-636.	0.6	147
6	DNMT3A in Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a030320.	2.9	135
7	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015, 125, 3455-3465.	0.6	124
8	CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. <i>Leukemia</i> , 2021, 35, 75-89.	3.3	107
9	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010, 116, 3907-3922.	0.6	100
10	Aerobic Plus Resistance Exercise in Obese Older Adults Improves Muscle Protein Synthesis and Preserves Myocellular Quality Despite Weight Loss. <i>Cell Metabolism</i> , 2019, 30, 261-273.e6.	7.2	77
11	Nutrient-sensitive transcription factors TFEB and TFE couple autophagy and metabolism to the peripheral clock. <i>EMBO Journal</i> , 2019, 38, .	3.5	58
12	Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1180-1182.	13.9	56
13	CD200/OX2, a cell surface molecule with immunoregulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. <i>British Journal of Haematology</i> , 2009, 145, 665-667.	1.2	51
14	How I diagnose and treat NPM1-mutated AML. <i>Blood</i> , 2021, 137, 589-599.	0.6	47
15	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	7.7	38
16	Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. <i>Cancer Discovery</i> , 2022, 12, 220-235.	7.7	38
17	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. <i>Leukemia</i> , 2017, 31, 1238-1240.	3.3	37
18	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. <i>British Journal of Haematology</i> , 2015, 170, 305-322.	1.2	36

#	ARTICLE	IF	CITATIONS
19	Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1511-E1519.	3.3	35
20	TFEB regulates murine liver cell fate during development and regeneration. <i>Nature Communications</i> , 2020, 11, 2461.	5.8	32
21	New insights into the biology of acute myeloid leukemia with mutated NPM1. <i>International Journal of Hematology</i> , 2019, 110, 150-160.	0.7	30
22	Novel <i>NPM1</i> exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	0.6	30
23	Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. <i>Blood Advances</i> , 2020, 4, 3357-3367.	2.5	27
24	Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion. <i>Cell Stem Cell</i> , 2020, 27, 326-335.e4.	5.2	25
25	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. <i>Leukemia</i> , 2021, 35, 2552-2562.	3.3	25
26	Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	23
27	Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. <i>Leukemia</i> , 2021, 35, 3113-3126.	3.3	22
28	It's All About MEIs: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice. <i>Cancer Cell</i> , 2020, 37, 267-269.	7.7	20
29	CD123 Is Consistently Expressed on NPM1-Mutated AML Cells. <i>Cancers</i> , 2021, 13, 496.	1.7	20
30	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. <i>Haematologica</i> , 2022, 107, 887-898.	1.7	15
31	Effect of the COVID-19 Pandemic on Laboratory and Clinical Research: A Testimony and a Call to Action From Researchers. <i>HemaSphere</i> , 2020, 4, e499.	1.2	14
32	PU.1 subcellular localization in acute myeloid leukaemia with mutated <i>NPM1</i> . <i>British Journal of Haematology</i> , 2020, 188, 184-187.	1.2	10
33	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. <i>Leukemia</i> , 2021, 35, 1949-1963.	3.3	10
34	Modeling <i>IKZF1</i> lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. <i>Blood Advances</i> , 2021, 5, 3876-3890.	2.5	6
35	Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19. <i>Blood</i> , 2016, 128, 4560-4560.	0.6	4
36	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. <i>Leukemia</i> , 2022, , .	3.3	2

#	ARTICLE	IF	CITATIONS
37	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. <i>Blood</i> , 2018, 132, 549-549.	0.6	1
38	CD200: a New Target for Immunotherapy in Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 1598-1598.	0.6	1
39	Response to: "Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukemia is obscured by paraformaldehyde fixation" <i>British Journal of Haematology</i> , 2020, 189, 577-578.	1.2	0
40	Prenatal diagnosis of familial hemophagocytic lymphohistiocytosis: morphological findings in the product of conception. <i>Annals of Hematology</i> , 2021, 100, 585-586.	0.8	0
41	Acute Myeloid Leukemia with Mutated NPM1 Presenting with Life-Threatening, Either Arterial or Venous, Thromboembolism: a Report of 4 Cases.. <i>Blood</i> , 2009, 114, 4135-4135.	0.6	0
42	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. <i>Blood</i> , 2009, 114, 480-480.	0.6	0
43	Fast and Efficient Gene Editing in Human Hematopoietic Cells. <i>Blood</i> , 2016, 128, 4704-4704.	0.6	0
44	Abstract 1031: Nuclear relocalization of NPM1c induces terminal differentiation and cell growth arrest. , 2017, , .		0
45	Acute Myeloid Leukemia with Mutated <i>NPM1</i> Is Dependent on the Cytoplasmic Localization of NPM1c. <i>Blood</i> , 2017, 130, 877-877.	0.6	0